论文部分内容阅读
AIM:To explore the therapeutic role of globular adiponectin(gAd)in high-fat diet/streptozotocin(STZ)-induced type 2 diabetic rats with nonalcoholic fatty liver disease(NAFLD).METHODS:Seven rats were fed a basic diet(normal control group;NC)during the experiment.Experimental rats(14 rats)were given a high-fat diet for 4 wk and were then injected with STZ to induce type 2 diabetes mellitus(T2DM)and NAFLD.Half of the T2DM/NAFLD rats were randomly injected intraperitoneally with gAd for 7 d(gAd-treated group),while the other 7 rats(T2DM/NAFLD group)received 0.9%saline.Plasma biochemical parameters and insulin concentrations were measured.Liver histopathology was examinedby hematoxylin-eosin staining.Insulin receptor expression in the liver was analyzed by immunohistochemical staining,Western blot and quantitative real-time reverse transcription polymerase chain reaction analysis.RESULTS:Compared to the control group,the T2DM/NAFLD group had increased levels of glucolipid and decreased levels of insulin.Plasma glucose and lipid levels were decreased in the gAd-treated group,while serum insulin levels increased.The expression of insulin receptor in the T2DM/NAFLD group increased compared with the NC group,and gAd downregulated insulin receptor expression in the livers of T2DM/NAFLD rats.Steatosis of the liver was alleviated in the gAd-treated group compared to the T2DM/NAFLD group(NAS 1.39±0.51 vs 1.92±0.51,P<0.05).CONCLUSION:Globular adiponectin exerts beneficial effects in T2DM rats with NAFLD by promoting insulin secretion,mediating glucolipid metabolism,regulating insulin receptor expression and alleviating hepatic steatosis.
AIM: To explore the therapeutic role of globular adiponectin (gAd) in high-fat diet / streptozotocin (STZ) -induced type 2 diabetic rats with nonalcoholic fatty liver disease (NAFLD). METHODS: Seven rats were fed a basic diet (14 rats) were given a high-fat diet for 4 wk and were then injected with STZ to induce type 2 diabetes mellitus (T2DM) and NAFLD. Half of the T2DM / NAFLD rats were randomized intraperitoneally with gAd for 7 d (gAd-treated group), while the other 7 rats (T2DM / NAFLD group) received 0.9% saline. Plasm biochemical parameters and the insulin concentrations were measured. Liver histopath was was examined by hematoxylin- eosin staining. Insulin receptor expression in the liver was analyzed by immunohistochemical staining, Western blot and quantitative real-time reverse transcription polymerase chain reaction analysis .RESULTS: Compared to the control group, the T2DM / NAFLD group had increased levels of glucolipid and decreased leve ls of insulin. Plasma glucose and lipid levels were decreased in the gAd-treated group, while serum insulin levels increased. The expression of insulin receptor in the T2DM / NAFLD group increased compared with the NC group, and gAd downregulated insulin receptor expression in the livers of T2DM / NAFLD rats. Steatosis of the liver was alleviated in the gAd-treated group compared to the T2DM / NAFLD group (NAS 1.39 ± 0.51 vs 1.92 ± 0.51, P <0.05) .CONCLUSION: Globular adiponectin exerts beneficial effects in T2DM rats with NAFLD by promoting insulin secretion, mediating glucolipid metabolism, regulating insulin receptor expression and alleviating hepatic steatosis.